OncLive TV

Julia K. Rotow, MD, discusses how T-DXd, zongertinib, and sevabertinib may be sequenced in first-line HER2-mutant NSCLC and why resistance profiling at progression matters.

Julia K. Rotow, MD, discusses subgroup results and post-progression treatment imbalances in the phase 3 DESTINY-Lung04 trial of first-line T-DXd in HER2-mutant NSCLC.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

David R. Gandara, MD, discusses why KRAS G12C predicted outsized benefit with first-line cemiplimab in PD-L1–high NSCLC and what it means for trial design.

Luis E. Raez, MD, discusses how oral TKIs may shift frontline sequencing across ROS1-positive, HER2-mutant, and EGFR exon 20 insertion–positive NSCLC.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.

Luis E. Raez, MD, discusses molecular testing, screening gaps, and global drug access challenges in lung cancer across Latin America and the US.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses phase 1 dose-optimization data supporting the 2.5 mg/kg dose of iza-bren in EGFR-mutated NSCLC.

Stephen V. Liu, MD, discusses building on durvalumab consolidation with tarlatamab and other novel agents in limited-stage SCLC.

Enriqueta Felip, MD, PhD, discusses selecting next-generation ROS1 TKIs after progression on crizotinib or entrectinib in NSCLC.

Luis Paz-Ares, MD, PhD, discusses protocols for managing T-cell engager and antibody-drug conjugate toxicities in lung cancer.

Tetsuya Mitsudomi, MD, PhD, discusses classifying and individualizing treatment for uncommon EGFR mutations in NSCLC.

Yang Xia, MD, PhD, discusses strategies for overcoming EGFR TKI resistance, including biomarker-selected and -unselected approaches.

Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.

Grant outlines open questions in perioperative NSCLC, from neoadjuvant sequencing and adjuvant selection to whether ctDNA is ready for practice.

A hematology-oncology fellow explains how trainees can use poster walks, follow-up contact, and review articles to find mentors and generate research questions.

Prithviraj Bose, MD, discusses selinexor's existing myeloma approval and how phase 3 SENTRY data could shape its use with ruxolitinib in myelofibrosis.

Naseema Gangat, MBBS, reviews cohort-specific hematologic response rates and safety findings for selcodebart in myelofibrosis.

David Sallman, MD, discusses planned development and combination strategies for the NEK7 inhibitor ofirnoflast in lower-risk MDS.

Naseema Gangat, MBBS, discusses phase 2 efficacy and safety data for DISC-3405, an anti-TMPRSS6 monoclonal antibody, in polycythemia vera.

E. Anders Kolb, MD, breaks down a new way to measure how blood cancer treatment advances translate into years of life saved.

David B. Sykes, MD, PhD, discusses the rationale for exploring the oral CXCR4 antagonist mavorixafor in patients with chronic neutropenia.

Aaron Gerds, MD, MS, discusses how platelet count and anemia guide JAK inhibitor selection for patients with myelofibrosis.

Brandon Huffman, MD, discusses INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.

Hagop M. Kantarjian, MD, discusses 5-year OPTIC trial data supporting a response-based, dose-reduction strategy for ponatinib in chronic-phase CML.

Ruben Mesa, MD, FACP, discusses the FDA approval of ropeginterferon alfa-2b-njft and the unmet need it addresses in essential thrombocythemia.

Uma Borate, MBBS, discusses reducing treatment toxicity in older patients with AML and the potential for time-limited therapy strategies.